イブジラスト
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/02/16 20:33:45」(JST)
[Wiki en表示]
Ibudilast
|
Systematic (IUPAC) name |
2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one |
Clinical data |
AHFS/Drugs.com |
International Drug Names |
Pregnancy cat. |
? |
Legal status |
? |
Identifiers |
CAS number |
50847-11-5 Y |
ATC code |
R03DC04 |
PubChem |
CID 3671 |
DrugBank |
DB05266 |
ChemSpider |
3543 N |
UNII |
M0TTH61XC5 N |
KEGG |
D01385 Y |
ChEMBL |
CHEMBL19449 N |
Chemical data |
Formula |
C14H18N2O |
Mol. mass |
230.31 g/mol |
N (what is this?) (verify)
|
Ibudilast (current development codes: AV-411 or MN-166) is an antiinflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE-4 subtype to the greatest extent,[1] but also showing significant inhibition of other PDE subtypes.[2][3]
Ibudilast has bronchodilator, vasodilator [4] and neuroprotective effects,[5][6] and is mainly used in the treatment of asthma and stroke.[7] It inhibits platelet aggregation,[8] and may also be useful in the treatment of multiple sclerosis.[9]
Ibudilast crosses the blood–brain barrier and suppresses glial cell activation. This activity has been shown to make ibudilast useful in the treatment of neuropathic pain and it not only enhances analgesia produced by opioid drugs, but also reduces the development of tolerance.[10]
References
- ^ Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sciences. 2006 May 1;78(23):2663-8.
- ^ Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Research. 1999 Aug 7;837(1-2):203-12.
- ^ Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. European Journal of Pharmacology. 2006 May 24;538(1-3):39-42.
- ^ Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovascular Drug Reviews. 2001 Fall;19(3):215-25.
- ^ Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004 Mar;46(3):404-11.
- ^ Yoshioka M, Suda N, Mori K, Ueno K, Itoh Y, Togashi H, Matsumoto M. Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia. Pharmacological Research. 2002 Apr;45(4):305-11.
- ^ Wakita H, Tomimoto H, Akiguchi I, Lin JX, Ihara M, Ohtani R, Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Research. 2003 Nov 28;992(1):53-9.
- ^ Rile G, Yatomi Y, Qi R, Satoh K, Ozaki Y. Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells. Thrombosis Research. 2001 May 1;102(3):239-46.
- ^ Feng J, Misu T, Fujihara K, Sakoda S, Nakatsuji Y, Fukaura H, Kikuchi S, Tashiro K, Suzumura A, Ishii N, Sugamura K, Nakashima I, Itoyama Y. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Multiple Sclerosis. 2004 Oct;10(5):494-8.
- ^ Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opinion on Investigational Drugs. 2007 Jul;16(7):935-50.
Phosphodiesterase inhibitors
|
|
PDE1 |
- MMPX
- SCH-51866
- Vinpocetine
|
|
PDE2 |
|
|
PDE3 |
- Amrinone
- Anagrelide
- Bucladesine
- Cilostamide
- Cilostazol
- Enoximone
- KMUP-1
- Milrinone
- Quazinone
- RPL-554
- Siguazodan
- Trequinsin
- Vesnarinone
- Zardaverine
|
|
PDE4 |
- Arofylline
- Cilomilast
- CP-80633
- Denbutylline
- Drotaverine
- Etazolate
- Filaminast
- Glaucine
- HT-0712
- Ibudilast
- ICI-63197
- Irsogladine
- Luteolin
- Mesembrine
- Piclamilast
- Roflumilast
- Rolipram
- Ro20-1724
- RPL-554
- YM-976
|
|
PDE5 |
- Acetildenafil
- Aildenafil
- Avanafil
- Dipyridamole
- Icariin
- Lodenafil
- Mirodenafil
- MY-5445
- Nitrosoprodenafil
- Sildenafil
- Sulfoaildenafil
- T-0156
- Tadalafil
- Udenafil
- Vardenafil
|
|
PDE6 |
|
|
PDE7 |
|
|
PDE9 |
|
|
PDE10 |
- Papaverine
- PF-2545920
- Tofisopam
|
|
Nonselective |
- Caffeine
- Doxofylline
- IBMX
- Pentoxifylline
- Propentofylline
- Theophylline
|
|
English Journal
- Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disorders.
- Coiro P1, Padmashri R1, Suresh A1, Spartz E1, Pendyala G1, Chou S2, Jung Y1, Meays B1, Roy S1, Gautam N3, Alnouti Y3, Li M2, Dunaevsky A4.
- Brain, behavior, and immunity.Brain Behav Immun.2015 Nov;50:249-58. doi: 10.1016/j.bbi.2015.07.022. Epub 2015 Jul 26.
- Both genetic and environmental factors are thought to contribute to neurodevelopmental and neuropsychiatric disorders with maternal immune activation (MIA) being a risk factor for both autism spectrum disorders and schizophrenia. Although MIA mouse offspring exhibit behavioral impairments, the synap
- PMID 26218293
- Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats.
- Zamberletti E1, Gabaglio M2, Prini P2, Rubino T2, Parolaro D3.
- European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.Eur Neuropsychopharmacol.2015 Oct 20. pii: S0924-977X(15)00323-5. doi: 10.1016/j.euroneuro.2015.09.021. [Epub ahead of print]
- Over 180 million people consume cannabis globally. Cannabis use peaks during adolescence with a trend for continued consumption by adults. Notably, several studies have shown that long-term and heavy cannabis use during adolescence can impair brain maturation and predispose to neurodevelopmental dis
- PMID 26499171
- Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.
- Johnson JL1, Kwok YH1, Sumracki NM1, Swift JE1, Hutchinson MR2, Johnson K3, Williams DB4, Tuke J5, Rolan PE1,6,7.
- Headache.Headache.2015 Oct;55(9):1192-208. doi: 10.1111/head.12655. Epub 2015 Sep 14.
- BACKGROUND: Medication overuse headache (MOH) is a condition bordering between a chronic pain condition and a substance dependence disorder. Activation of immunocompetent glial cells in the central nervous system has been linked to both pathological pain and drug addiction/reward. Preclinically, ibu
- PMID 26367865
Japanese Journal
- Ibudilast Inhibits Th17 Cell Differentiation from Naïve Human T Cells
- ラット中大脳動脈永久閉塞モデルにおけるイブジラストの脳保護効果の検討
- ラット心房筋細胞におけるM_2受容体刺激で誘起されるK^+電流応答に対するibudilastの抑制効果
Related Links
- [Ibudilast] [50847-11-5] | 価格や在庫、物性値などの詳細情報ページです。 ... ・川口の在庫は即日,つくばの在庫は2〜3日以内の出荷となります。・詳細につきましては,お手数ですが営業部までお問い合わせください。
- Read about the experimental therapy Ibudilast (MN-166) for Multiple Sclerosis, ALS, and Methamphetamine Addiction, currently in development by MediciNova. ... Ibudilast, labeled MN-166 by MediciNova, is a potential oral treatment ...
Related Pictures
★リンクテーブル★
[★]
- 英
- ibudilast
- 商
- アイビナール、ケタス、ピナトス